VYNE Therapeutics Statistics Share Statistics VYNE Therapeutics has 16.66M
shares outstanding. The number of shares has increased by 12.99%
in one year.
Shares Outstanding 16.66M Shares Change (YoY) 12.99% Shares Change (QoQ) 9.57% Owned by Institutions (%) 16.78% Shares Floating 13.63M Failed to Deliver (FTD) Shares 4,852 FTD / Avg. Volume 0.7%
Short Selling Information The latest short interest is 333.48K, so 2% of the outstanding
shares have been sold short.
Short Interest 333.48K Short % of Shares Out 2% Short % of Float 2.02% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -3.58 and the forward
PE ratio is -1.96.
VYNE Therapeutics's PEG ratio is
0.05.
PE Ratio -3.58 Forward PE -1.96 PS Ratio 284.78 Forward PS 1.8 PB Ratio 2.74 P/FCF Ratio -4.19 PEG Ratio 0.05
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for VYNE Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 4.35,
with a Debt / Equity ratio of 0.
Current Ratio 4.35 Quick Ratio 4.35 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $38.54K Profits Per Employee $-3.06M Employee Count 13 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax 4K Effective Tax Rate -0.01%
Stock Price Statistics The stock price has increased by -23.68% in the
last 52 weeks. The beta is 1.78, so VYNE Therapeutics's
price volatility has been higher than the market average.
Beta 1.78 52-Week Price Change -23.68% 50-Day Moving Average 1.18 200-Day Moving Average 2.06 Relative Strength Index (RSI) 55.67 Average Volume (20 Days) 695,072
Income Statement In the last 12 months, VYNE Therapeutics had revenue of 501K
and earned -39.83M
in profits. Earnings per share was -0.93.
Revenue 501K Gross Profit 501K Operating Income -43.64M Net Income -39.83M EBITDA -43.63M EBIT -43.64M Earnings Per Share (EPS) -0.93
Full Income Statement Balance Sheet The company has 19.93M in cash and 99K in
debt, giving a net cash position of 19.83M.
Cash & Cash Equivalents 19.93M Total Debt 99K Net Cash 19.83M Retained Earnings -731.17M Total Assets 56.42M Working Capital 42.62M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -33.97M
and capital expenditures -117K, giving a free cash flow of -34.09M.
Operating Cash Flow -33.97M Capital Expenditures -117K Free Cash Flow -34.09M FCF Per Share -0.8
Full Cash Flow Statement Margins Gross margin is 99.2%, with operating and profit margins of -8709.98% and -7950.9%.
Gross Margin 99.2% Operating Margin -8709.98% Pretax Margin -7944.71% Profit Margin -7950.9% EBITDA Margin -8709.18% EBIT Margin -8709.98% FCF Margin -6804.19%
Dividends & Yields VYNE does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for VYNE is $6.25,
which is 331% higher than the current price. The consensus rating is "Buy".
Price Target $6.25 Price Target Difference 331% Analyst Consensus Buy Analyst Count 2
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Feb 13, 2023. It was a
backward
split with a ratio of 1:18.
Last Split Date Feb 13, 2023 Split Type backward Split Ratio 1:18
Scores Altman Z-Score -19.28 Piotroski F-Score 1
